Autor según el artículo: Sánchez-López E, Ettcheto M, Egea MA, Espina M, Calpena AC, Folch J, Camins A, García ML.
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: FOLCH LOPEZ, JAUME
Palabras clave: nanoparticles Alzheimer's disease
Resumen: Dexibuprofen loaded pegylated poly(lactic-co-glycolic) nanospheres prepared by solvent diffusion method were designed to increase Dexibuprofen brain delivery reducing systemic side effects. Nanospheres exhibited a mean particle size around 200 nm (195.4 nm), monomodal population and negative surface charge. Drug loaded nanospheres showed a sustained release profile, allowing to modify the posology in vivo. Nanospheres were non-toxic neither in brain endothelial cells nor astrocytes and do not cause blood–brain barrier disruption. Nanospheres were able to partially cross the cells barrier and release the drug after co-culture in vitro experiments, increasing Dexibuprofen permeation coefficient. Behavioral tests performed in APPswe/PS1dE9 mice (mice model of familial Alzheimer's disease) showed that nanospheres reduce memory impairment more efficiently than the free drug. Developed nanospheres decrease brain inflammation leading to β-amyloid plaques reduction. According to these results, chronical oral Dexibuprofen pegylated poly(lactic-co-glycolic) nanosystems could constitute a suitable strategy for the prevention of neurodegeneration.
Grupo de investigación: Farmacobiologia Cel.lular
Áreas temáticas: Biochemistry and technology Bioquímica y tecnología Bioquímica i biotecnologia
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 1549-9634
Fecha de alta del registro: 2017-03-07
Página final: 1182
Volumen de revista: 13
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2017
Página inicial: 1171
Tipo de publicación: Article Artículo Article
Repositori URV